Swelling and pain at injection site within a few minutes of injection; Swelling and pain at injection site within a few minutes of injection; Fever 100.3 x 5 days,tapering to intermittent spikes up to 100.3 x 5 more days; Joint pain; body aches; migraine; nausea x 10 days; Fatigue; malaise x 14 days; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 56 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 23Jun2021 18:15 (Lot number: 30130BA) at the age of 56 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Lupus (SLE)" (unspecified if ongoing); "immune-mediated thrombocytopenia purpura" (unspecified if ongoing); "remission/splenectomy 2001", start date: 2001 (unspecified if ongoing); "asthma" (unspecified if ongoing); "chronic migraines" (unspecified if ongoing); "chronic gastritis" (unspecified if ongoing); "Latex allergy" (unspecified if ongoing); "Allergy to molds" (unspecified if ongoing); "Allergy to fungi" (unspecified if ongoing); "Allergy to corn" (unspecified if ongoing); "Allergy to citrus fruits/banana" (unspecified if ongoing); "Allergy to almond/ hazeln" (unspecified if ongoing); "Allergy to sulfates/sulphites/citric acid/citrate" (unspecified if ongoing). Concomitant medication(s) included: PLAQUENIL S; LYRICA; VIT D [ERGOCALCIFEROL].  The following information was reported: VACCINATION SITE SWELLING (non-serious), VACCINATION SITE PAIN (non-serious) all with onset 23Jun2021 18:30, outcome "recovered" (2021) and all described as "Swelling and pain at injection site within a few minutes of injection"; PYREXIA (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "Fever 100.3 x 5 days,tapering to intermittent spikes up to 100.3 x 5 more days"; ARTHRALGIA (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "Joint pain"; PAIN (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "body aches"; MIGRAINE (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "migraine"; NAUSEA (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "nausea x 10 days"; FATIGUE (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "Fatigue"; MALAISE (non-serious) with onset 23Jun2021 18:30, outcome "recovered" (2021), described as "malaise x 14 days". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vaccination site swelling, vaccination site pain, pyrexia, arthralgia, pain, migraine, nausea, fatigue, malaise.  Additional information: The patient received concomitant medication within two weeks of vaccination. No other vaccine was administered within four weeks. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The clinical course was as follows: The patient experienced Swelling and pain at injection site within a few minutes of injection, lasting 5 days. Fever 100.3 x 5 days, tapering to intermittent spikes up to 100.3 x 5 more days. Joint pain, body aches, migraine, nausea x 10 days. Fatigue, malaise x 14 days.  Follow-up attempts are completed. No further information is expected.